|Year : 2019 | Volume
| Issue : 3 | Page : 237-239
Primary prostatic extra-gastrointestinal stromal tumor causing giant prostatomegaly
Gaurav Garg, Ashish Sharma, Satya Narayan Sankhwar
Department of Urology, KGMU, Lucknow, Uttar Pradesh, India
|Date of Submission||05-Feb-2019|
|Date of Acceptance||12-May-2019|
|Date of Web Publication||2-Jul-2019|
Department of Urology, KGMU, Lucknow, Uttar Pradesh
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Prostatic extra-gastrointestinal stromal tumors (E-GIST) are rare mesenchymal tumors with only 9-cases reported in the English literature so far. We herein describe a case of E-GIST causing massive enlargement of the prostate gland. A 55-year-old male was diagnosed with localized prostatic E-GIST causing massive prostatomegaly (1230 cc) during workup for lower urinary tract symptoms (LUTS). The patient was managed with Imatinib mesylate therapy as high anesthetic risks precluded surgery. Given the rarity, E-GISTs should be included in the differential diagnosis of patients presenting with LUTS as it may influence the treatment decisions.
|How to cite this article:|
Garg G, Sharma A, Sankhwar SN. Primary prostatic extra-gastrointestinal stromal tumor causing giant prostatomegaly. Indian J Urol 2019;35:237-9
| Introduction|| |
Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors originating from the digestive tract, commonly the stomach. Extra-GISTs (E-GISTs) are morphologically, immunophenotypically, and histologically similar to GIST but arise outside the gastrointestinal tract. E-GISTs of the prostate are rare with less than 10 cases reported in the English literature till date.,,,,,,,, We present the case of a 55-year-old male diagnosed with prostatic E-GIST during workup for lower urinary tract symptoms (LUTS) managed with medical therapy. The present case is the tenth case of prostatic E-GIST. We also reviewed the relevant literature focusing on the clinical presentation, diagnosis, and the outcomes of E-GIST of the prostate.
| Case Report|| |
A 55-year-old male with history of ischemic heart disease, presented with bothersome LUTS of 6 months duration. Digital rectal examination revealed massively enlarged nodular prostate and the serum PSA was 3.2 ng/ml. A standard 12-core transrectal ultrasound guided prostatic biopsy was performed which showed multiple spindle cells which stained positive for c-kit, CD117 and CD34 on immunehistochemistry, consistent with a diagnosis of primary prostatic GIST [Figure 1]. Ultrasonography and computed tomography scan of the abdomen and pelvis revealed a massively enlarged (1230 cc) prostate filling the entire pelvic cavity and extending into the rectum and the seminal vesicles [Figure 2]. Metastatic workup was negative. As the patient was a known case of heart disease (New York Heart Association Class III), he was deemed high risk for surgical intervention. Hence, after surgical/radiation oncologist's consult and taking the patient's wish, into account, he was started on imatinib mesylate therapy (tyrosine-kinase inhibitor). The patient reported mild-to-moderate improvement in LUTS (as measured by the decline in the International Prostate Symptom Score) with a reduction in size of the prostatic mass on repeat imaging at 12-month follow-up.
|Figure 1: Photomicrograph showing multiple spindle cells disposed in intersecting fascicles|
Click here to view
|Figure 2: Coronal computed tomography scan image of the patient showing massively enlarged homogeneously enhancing prostate filling almost the entire pelvic cavity|
Click here to view
| Discussion|| |
The first case of prostatic E-GIST was reported by Van Der Aa et al. in 2005. A review of the available case reports and comparison with the present case is presented in [Table 1]. The age at presentation has varied widely (ranging from 31 to 75 years) in the previously published reports. The clinical presentation is also variable but generally includes voiding LUTS, hematuria, acute urinary retention, perineal pain, or an abnormal rectal examination. Usually, the patient has grossly enlarged prostate gland with no/mild elevation in serum PSA levels. There are no characteristic radiographic features, and the mainstay of diagnosis are the histopathological findings along with immunohistochemistry.,, Majority of the E-GISTs (>95%) express CD117, whereas around 50%–100% express CD34 antigen.,, In some cases, positive staining for S100 protein, desmin, or smooth muscle actin may also be seen., The present case also had spindle cells which stained positive for CD117 and CD34, which is characteristic of E-GISTs. Due to rarity of the disease, standard management protocols for E-GISTs are unavailable, and the treatment is based on extrapolated data on GISTs. For nonmetastatic E-GISTs, radical prostatectomy has been reported, whereas metastatic cases and recurrences have been managed by targeted therapy with tyrosine kinase inhibitors (imatinib mesylate). Imatinib mesylate therapy is also recommended high-risk patients or patients with advanced disease before and after surgical treatment. The present case is unique because of the massive size of the prostate, the second largest prostate gland volume ever reported. E-GISTs confined to the prostate that are managed by radical prostatectomy, seldom reccurd. Managing prostatic E-GIST with giant prostates (>500cc) is challenging for the clinicians. Advanced age and medical comorbidities such as the ischemic heart disease add to the surgical risks. In the present case, in view of high surgical risk of prostatectomy, a decision was made to start imatinib mesylate therapy after consulting medical oncologist.
| Conclusion|| |
Given the rarity, E-GISTs should be included in the differential diagnosis of patients presenting with LUTS as it may influence the treatment decisions.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due effort will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship: Nil.
Conflicts of interest: There are no conflicts of interest.
| References|| |
Van der Aa F, Sciot R, Blyweert W, Ost D, Van Poppel H, Van Oosterom A, et al.
Gastrointestinal stromal tumor of the prostate. Urology 2005;65:388.
Lee CH, Lin YH, Lin HY, Lee CM, Chu JS. Gastrointestinal stromal tumor of the prostate: A case report and literature review. Hum Pathol 2006;37:1361-5.
Yinghao S, Bo Y, Xiaofeng G. Extragastrointestinal stromal tumor possibly originating from the prostate. Int J Urol 2007;14:869-71.
Ou Z, Cao Z, He Y, Tang D. Diagnosis and multimodal therapy for extragastrointestinal stromal tumor of the prostate: A case report. Exp Ther Med 2013;6:378-80.
Liu S, Yu Q, Han W, Qi L, Zu X, Zeng F, et al.
Primary gastrointestinal stromal tumor of the prostate: A case report and literature review. Oncol Lett 2014;7:1925-9.
Zhang ZH, Feng GW, Liu ZF, Qiao L, Zhang T, Gao C, et al.
Ayoung man with primary prostatic extra-gastrointestinal stromal tumor: A rare case report and review of the literature. Int J Clin Exp Pathol 2014;7:1764-70.
Etit D, Kar H, Ekinci N, Yenipazar AE, Çakalaǧaoǧlu F. Extra-gastrointestinal stromal tumor of prostate. Balkan Med J 2017;34:168-71.
You YH, Zhang Y. Primary prostatic extragastrointestinal stromal tumor: A case report and literature review. J Int Med Res 2018;46:4343-9.
Almagharbi SA, Fayoumi YA, Abdel-Meguid TA, Abdelsalam A, Bokhary RY, Azhar RA, et al.
Extragastrointestinal stromal tumor of prostate. Urol Ann 2018;10:416-9.
] [Full text]
Maliakal J, Mousa EE, Menon V. Giant prostatic hyperplasia: Fourth largest prostate reported in medical literature. Sultan Qaboos Univ Med J 2014;14:e253-6.
[Figure 1], [Figure 2]
|This article has been cited by|
||Primary extragastrointestinal stromal tumors of the prostate: A case report and literature review
| ||Yuxuan Yang, Dengshun Sun, Kun Tang |
| ||Frontiers in Oncology. 2022; 12 |
|[Pubmed] | [DOI]|